Markets

Vaderis hauls in $152M to test an AKT-targeting drug

1 source ·1 article ·2h ago

The startup is one of at least a few young companies zeroing in on the rare bleeding disorder, hereditary hemorrhagic telangiectasia, with a more precise AKT blocker.

Covered by 1 outlet

Biopharmadive 1

All coverage · 1 article

BioPharma Dive ·2h ago

Vaderis hauls in $152M to test an AKT-targeting drug

The startup is one of at least a few young companies zeroing in on the rare bleeding disorder, hereditary hemorrhagic telangiectasia, with a more precise AKT blocker.

Vaderis hauls in $152M to test an AKT-targeting drug

Vaderis hauls in $152M to test an AKT-targeting drug →

Vaderis hauls in $152M to test an AKT-targeting drug